Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples

Area of Science:

• Pharmacogenomics
• Clinical Diagnostics
• Molecular Biology

Background:

• Clopidogrel, a prodrug metabolized by CYP2C19, is crucial post-percutaneous coronary intervention (PCI).
• CYP2C19 genetic variations cause inter-individual differences in drug response, increasing cardiovascular event risk.
• Current clinical practice benefits from CYP2C19 genotyping to identify high-risk patients for tailored pharmacotherapy.

Purpose of the Study:

• To validate the Spartan RX CYP2C19 System using blood samples for improved clinical workflow.
• To assess the concordance and reproducibility of CYP2C19 genotyping from blood versus buccal swabs.
• To facilitate the integration of CYP2C19 genotyping into routine clinical care for genotype-guided therapy.

Main Methods:

• Validation of the Spartan RX CYP2C19 System using blood and buccal swab samples.
• Testing of 26 reference materials and samples from 23 patients/volunteers.
• Assessment of genotype concordance between blood and buccal samples and reproducibility across multiple runs.

Main Results:

• 100% concordance in genotype results between DNA from blood and buccal swabs.
• Genotype results were consistent with expected outcomes for reference materials.
• High reproducibility was demonstrated, with consistent results across multiple assay runs.

Conclusions:

• DNA extracted from blood is a viable source for Spartan RX CYP2C19 genotyping.
• Adapting the methodology to utilize blood samples successfully improved clinical workflow.
• This validated approach enables effective implementation of genotype-guided clopidogrel therapy in clinical practice.